Shteinfer-Kuzmine, A.; Argueti-Ostrovsky, S.; Leyton-Jaimes, M.F.; Anand, U.; Abu-Hamad, S.; Zalk, R.; Shoshan-Barmatz, V.; Israelson, A.
Targeting the Mitochondrial Protein VDAC1 as a Potential Therapeutic Strategy in ALS. Int. J. Mol. Sci. 2022, 23, 9946.
https://doi.org/10.3390/ijms23179946
AMA Style
Shteinfer-Kuzmine A, Argueti-Ostrovsky S, Leyton-Jaimes MF, Anand U, Abu-Hamad S, Zalk R, Shoshan-Barmatz V, Israelson A.
Targeting the Mitochondrial Protein VDAC1 as a Potential Therapeutic Strategy in ALS. International Journal of Molecular Sciences. 2022; 23(17):9946.
https://doi.org/10.3390/ijms23179946
Chicago/Turabian Style
Shteinfer-Kuzmine, Anna, Shirel Argueti-Ostrovsky, Marcel F. Leyton-Jaimes, Uttpal Anand, Salah Abu-Hamad, Ran Zalk, Varda Shoshan-Barmatz, and Adrian Israelson.
2022. "Targeting the Mitochondrial Protein VDAC1 as a Potential Therapeutic Strategy in ALS" International Journal of Molecular Sciences 23, no. 17: 9946.
https://doi.org/10.3390/ijms23179946
APA Style
Shteinfer-Kuzmine, A., Argueti-Ostrovsky, S., Leyton-Jaimes, M. F., Anand, U., Abu-Hamad, S., Zalk, R., Shoshan-Barmatz, V., & Israelson, A.
(2022). Targeting the Mitochondrial Protein VDAC1 as a Potential Therapeutic Strategy in ALS. International Journal of Molecular Sciences, 23(17), 9946.
https://doi.org/10.3390/ijms23179946